Mycophenolate mofetil (MMF) is widely used for maintenance immunosuppression in solid organ transplantation. Gastrointestinal toxicity, usually manifested as diarrhea, is the most common side effect of MMF. We evaluated colonic biopsies from 20 renal transplant patients with MMF-related diarrhea. The latter was defined by the absence of any other demonstrable etiology and improvement or resolution of symptoms by the discontinuation or reduction of the dose of MMF alone. These biopsies were compared with colon biopsies from patients with the following: acute graftversus-host disease (GVHD, n=10), inflammatory bowel disease (IBD) or infectious colitis (n=10), and colon biopsies from renal transplant patients not receiving MMF (n=8). Normal colonic segments from surgical specimens served as normal controls (n=5). Colonic biopsies from patients with MMF-related diarrhea showed prominent crypt cell apoptosis and reactive/reparative changes including enterocyte cytologic atypia, increased neuroendocrine cells, and glandular architectural distortion. The changes were similar, although of milder degree to the ones seen in patients with acute intestinal GVHD. This pattern of injury was not seen in controls or in biopsies from transplant patients not receiving MMF, and it was markedly different from the one seen in idiopathic inflammatory or infectious colitis. The severity of histologic changes correlated significantly with the endoscopic degree of "colitis." There was no statistically significant correlation between histologic damage and the dose of MMF (corrected for body weight and renal function). MMF-related colitis is a distinct entity that displays histologic features remarkably similar to the ones associated with intestinal GVHD. This form of injury could be related to either direct toxicity or an "innocent bystander" phenomenon secondary to the alteration of the immunologic microenvironment of the colon caused by the MMF.
1. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental mycophenolate mofetil renal transplantation study group. Transplantation5:1450-1454, 1998
3. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy17:1178-1197, 1997
4.
4. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf17:75-92, 1997
5.
5. Ducloux D, Ottignon Y, Semhoun-Ducloux S, Labre, S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation66:1115-1116, 1998
6.
6. Puig JM, Fernandez-Crespo P, Lloveras J, Mir M, Iniigo V, Manresa JM, Masramon J. Risk factors that influence the incidence and severity of MMF adverse events in renal transplant patients: Relationship with corticosteroid dosage, renal function, sex and patient age. Transplantation Proc31:2270-2271, 1999
7.
7. Golconda MS, Valente JF, Bejarano P, Gilinsky N, First MR. Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients. Transplant Proc31:272-273, 1999
8.
8. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant10:140-145, 1996
9.
9. Inoue H, Sugioka N, Hayashida K, Yasumura T. Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. Int J Urol4:279-284, 1997
10.
10. Papadimitriou JC, Drachenberg CB, Wiland A, et al. Histological morphology of colitis associated with mycophenolate mofetil (MMF) in renal allograft recipients: Acute graft-versus-host disease (GVHD)-like features. Transplantation67:S256-S256, 1999
11.
11. Berribi C, Loirat C, Jazqz-Aigrain E. Mycophenolate mofetil may induce apoptosis in duodenal villi. Pediatr Nephrol14:177-178, 2000
12.
12. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med101:421-428, 1984
13.
13. Lee EY, Clouse RE, Aliperti G, DeSchryver Kecskemeti K. Small intestinal lesion resembling graft-vs-host disease. Arch Pathol Lab Med115:529-532, 1991
14.
14. Wirt DP, Brooks EG, Vaidya S, Klimpel GR, Waldmann TA, Goldblum RM. Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. N Engl J Med321:370-374, 1989
15.
15. Snover DC, Filipovich AH, Ramsay NKC, Weisdorf SA, Kersey JH. Graft-versus-host disease-like histopathological findings in pre-bone marrow transplantation biopsies of patients with severe Tcell deficiency. Transplantation39:95-102, 1985
17. Bombi JA, Nadal A, Carreras E, Ramirez J, Munoz J, Rozman C, Cardesa A. Assessment of histopathologic changes in the colonic biopsy in acute graftversus-host disease. Am J Clin Pathol103:690-695, 1995
18.
18. Lee FD. Importance of apoptosis in the histopathology of drug related lesions in the large intestine. J Clin Pathol46:118-122, 1993
19.
19. Snover DC. Graft-versus-host disease of the gastrointestinal tract. Am J Surg Pathol14(Suppl):101-108, 1990
20.
20. Snover DC. Acute and chronic graft versus host disease: Histopathological evidence of two distinct pathogenetic mechanisms. Hum Pathol15:202-205, 1984
21.
21. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S, McGlave P. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol16:387-392, 1985
22.
22. Gleichmann E, Gleichmann H. Graft-versus-host reaction: A pathogenetic principle for the development of drug allergy, autoimmunity, and malignant lymphoma in non-chimeric individuals. Hypothesis. Cancer Res Clin Oncol85:91-109, 1976
23.
23. Nussler NC, Hoffman RA, McCarthy SA, Simmons RL. Functional changes of intestinal intraepithelial lymphocytes during acute graft versus host disease: Correlation with phenotype. Int Immunol8:1767-1777, 1996
24.
24. van Bekkum W, Knaan S. Brief communication: Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst58:787-790, 1977
25.
25. Elson CO, Reilly RW, Rosenberg IH. Small intestinal injury in the graft versus host reaction: An innocent bystander phenomenon. Gastroenterology72:886-889, 1977
27. Forbes GM, Erber WN, Herrmann RP, Davies JM, Collins BJ. Immunohistochemical changes in sigmoid colon after allogeneic and autologous bone marrow transplantation. J Clin Pathol48:308-313, 1995
28.
28. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood95:2754-2759, 2000
29.
29. Singh JN, Sabbadini E, Sehan AH. Cytotoxicity in graft-versus-host reaction. I. Role of donor and host spleen cells. J Exp Med136:39-48, 1972
30.
30. Washington K, Bentley RC, Green A, Olson J, Treem WR, Krigman HR. Gastric graft-versus-host disease. A blind histologic study. Am J Surg Pathol21:1037-1046, 1997
31.
31. Meisel JL, Bergman D, Graney D, Saunders DR, Rubin CE. Human rectal mucosa. Proctoscopic and morphological changes caused by laxatives. Gastroenterology72:1274-1279, 1977
32.
32. Khoury N, Ammor M, Durrbach A, Kriaa F, Bharpentier B: Colite diffuse associ6e a un traitement par mycophenolate mofetil: A propos d' une observation. Nephrologie21:437-439, 2000
33.
33. Lampert IA, Thorpe P, Van Norden S, et al. Selective sparing of enterochromaffin cells in graft-versushost disease affecting the colonic mucosa. Histopathology9:875-886, 1985
34.
34. Desperbasques M, Dhillon A, Hamid Q. Epithelial changes following bone marrow transplantation: Cytological atypia and epithelial endocrine cells. APMIS99:557-566, 1991
35.
35. Mitros FA. Atlas of gastrointestinal pathology. JB Lippincott Company, Philadelphia PA, pp. 7-28, 1988
36.
36. Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: A prospective study of thirteen patients. Gastroenterology78:764-771, 1980
37.
37. Asplund S, Gramlich TL. Chronic mucosal changes of the colon in graft-versus-host disease. Mod Pathol11:513-515, 1998
38.
38. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol135:1097-1103, 1989
39.
39. Beschorner WE, Shinn CA, Hess AD, Suresch DL, Santos GW. Immune-related injury to endothelium associated with acute graft-versus-host disease in the rat. Transplant Proc21:3025-3027, 1989
40.
40. Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Hiller E. Endothelial cell markers in bone marrow transplant recipients with and without acute graftversus-host disease. Bone Marrow Transplant19:909-914, 1997
41.
41. Durez P, Appelboom T, Pira C, Stordeur P, Vray B, Goldman M. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: Inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol21:581-587, 1999
42.
42. Jonsson CA, Erlandsson M, Svensson L, Molne J, Carlsten H. Mycophenolate mofetil ameliorates perivascular T-lymphocyte inflammation and reduces the double-negative T-cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol197:136-144, 1999
43.
43. Izeradjene K, Revillard JRApoptosis of superantigenactivated T-cell induced by mycophenolate mofetil treatment. Transplantation71:118-125, 2001
44.
44. Ming S-C, Goldman H. Pathology of the gastrointestinal tract. WB Saunders Company, Philadelphia, PA, p. 264-264, 1992
45.
45. Kaplan B, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, Gelfand E, Mulgaonkar S. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis34:65-68, 1999
46.
46. Guerard A, Rabodonirina M, Cote L, Liguory O, Piens MA, Daoud S, Picot S, Touraine JL. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation68:699-707, 1999
